Keyphrases
Gene Expression
100%
Lung
100%
NY-ESO-1
100%
Esophagus
100%
Patients with Cancer
100%
Phase I Study
100%
Pleura
100%
Decitabine
100%
Gene Expression Profile
66%
Gene Induction
66%
Thoracic Malignancy
66%
Quantitative PCR
33%
DNA Methylation (DNAm)
33%
Tumor Cells
33%
Immunohistochemical Method
33%
Neoplasms
33%
Cancer-testis Antigen
33%
Pharmacokinetics
33%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
33%
Cytotoxic Chemotherapy
33%
Cancer Cells
33%
Tumor Suppressor
33%
Gene Products
33%
Myelosuppression
33%
Malignant Transformation
33%
Quantitative Methylation-specific PCR (Q-MSP)
33%
Chemotherapy Regimen
33%
Tumor Tissue
33%
5-aza-2′-deoxycytidine
33%
Phase I Trial
33%
Objective Response
33%
Treatment Response
33%
Maximum Tolerated Dose
33%
Dose-limiting Toxicity
33%
Chromatin Remodeling
33%
Cancer Therapy
33%
MAGE-A3
33%
Dose Escalation
33%
Oligonucleotide Array
33%
PCR Method
33%
P16 Expression
33%
Induced Gene
33%
Tumor Biopsy
33%
Derepression
33%
Mass Spectrometry Methods
33%
Heterogeneous Gene Expression
33%
DNA Demethylating Agents
33%
Medicine and Dentistry
Gene Expression
100%
Esophagus
100%
Visceral Pleura
100%
Decitabine
100%
Neoplasm
40%
Infusion
40%
Thoracic Cancer
40%
Gene Induction
40%
Quantitative Reverse Transcription Polymerase Chain Reaction
20%
Tumor Cell
20%
Methylation
20%
Cancer Cell
20%
Polymerase Chain Reaction
20%
Cancer Therapy
20%
Gene Product
20%
Treatment Response
20%
Bone Marrow Suppression
20%
Malignant Transformation
20%
Chemotherapy Regimens
20%
Cytotoxic Chemotherapy
20%
Melanoma Antigen 3
20%
P16
20%
Pharmacokinetics
20%
Tumor Biopsy
20%
DNA Methylation
20%
Tumor Suppressor Protein
20%
Phase I Trials
20%
DNA Microarray
20%
Chromatin Remodeling
20%
Liquid Chromatography-Mass Spectrometry
20%
Cancer Testis Antigen
20%
Biochemistry, Genetics and Molecular Biology
Gene Expression
100%
Decitabine
100%
Esophagus
100%
Gene Induction
40%
Methylation
20%
DNA Methylation
20%
Cancer Cell
20%
Monospecific Antibody
20%
Chromatin Remodeling
20%
Polymerase Chain Reaction
20%
Pharmacokinetics
20%
Tumor Suppressor Protein
20%
Malignant Transformation
20%
Gene Product
20%
Quantitative Reverse Transcription Polymerase Chain Reaction
20%
P16
20%
DNA Microarray
20%
Maximum Tolerated Dose
20%
Phase I Trials
20%
Derepression
20%
Liquid Chromatography-Mass Spectrometry
20%
Demethylating Agent
20%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Malignant Neoplasm
100%
Decitabine
100%
Oligonucleotide
25%
Pharmacokinetics
25%
Cytotoxic Chemotherapy
25%
Bone Marrow Suppression
25%
Chemotherapy Regimens
25%
Tumor Suppressor Protein
25%
Maximum Tolerated Dose
25%
Phase I Trials
25%
Malignant Transformation
25%
Melanoma Antigen 3
25%
Cancer Testis Antigen
25%